Geode Capital Management LLC Purchases 32,551 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Geode Capital Management LLC grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,683,500 shares of the medical equipment provider’s stock after purchasing an additional 32,551 shares during the quarter. Geode Capital Management LLC owned approximately 2.42% of Lantheus worth $184,798,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Signaturefd LLC boosted its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. bought a new position in shares of Lantheus in the 3rd quarter worth $51,000. GAMMA Investing LLC increased its holdings in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares during the last quarter. Finally, Nkcfo LLC bought a new stake in Lantheus in the second quarter valued at about $47,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on LNTH shares. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Truist Financial reissued a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reduced their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $130.00.

Lantheus Stock Performance

Shares of LNTH stock opened at $93.02 on Monday. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company’s 50 day moving average price is $97.88 and its two-hundred day moving average price is $98.11. The company has a market capitalization of $6.47 billion, a P/E ratio of 15.48 and a beta of 0.45.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.